Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Lisa C Holthof, Dept. of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam.
  • ,
  • Hilma J van der Horst, Dept. of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam.
  • ,
  • Susan E van Hal-van Veen, Dept. of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam.
  • ,
  • Ruud W J Ruiter, Dept. of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam.
  • ,
  • Fengzhi Li, Dept. of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, New York, USA.
  • ,
  • Marijke Buijze, Dept.Otolaryngology-Head and Neck Surgery, Amsterdam UMC, VU University Medical Center,Cancer Center.
  • ,
  • Morten N Andersen
  • Huipin Yuan, Kuros Biosciences BV, Bilthoven, The Netherlands.
  • ,
  • Joost de Bruijn, Kuros Biosciences BV, Bilthoven and Queen Mary University of London.
  • ,
  • Niels W C J van de Donk, Dept. of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam.
  • ,
  • Henk M Lokhorst, Dept. of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam.
  • ,
  • Sonja Zweegman, Dept. of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam.
  • ,
  • Richard W J Groen, Dept. of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam.
  • ,
  • Tuna Mutis, Dept. of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam; t.mutis@vumc.nl.
Original languageEnglish
JournalHaematologica
Volume105
Issue2
Pages (from-to)e80-e83
Number of pages4
ISSN0390-6078
DOIs
Publication statusPublished - 2020

See relations at Aarhus University Citationformats

ID: 154896715